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Abstract 
 
The Genomic Medicine Alliance [http://www.genomicmedicinealliance.org] is a 
newly created global academic research network that aims to establish and strengthen 
collaborative ties between academics, researchers, regulators and members of the public who 
are interested in genomic medicine. Its focus lies on the translation of scientific research 
findings into clinical practice. It brings together experts from disciplines including genome 
informatics, pharmacogenomics, public health genomics, ethics in genomics and health 
economics, and are supervised by a 14 member International Scientific Advisory Committee, 
comprising internationally renowned scientists. The Alliance’s official journal, Public Health 
Genomics, offers members a highly respected publication forum for their original research 
findings. In the short to medium term, the Genomic Medicine Alliance hopes to broaden its 
membership significantly, and to initiate new projects not only to promote the translation of 
genomics research into clinical practice but also to harmonize research activities between 
developed and developing countries. It also seeks to support the mobility of early-stage 
researchers and scientists across borders, and the organization of educational activities in the 
field of Genomic Medicine. 
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Introduction 
 
The central aim of genomic medicine is to utilize the individual’s genomic 
information to support the clinical decision-making process [1]. In recent years, significant 
advances have been made in understanding the molecular etiology of a wide range of human 
genetic diseases. These advances have the potential to improve disease prognosis and 
treatment [2]. In parallel, genomic technology has progressed rapidly, prompting the 
replacement of low-throughput genetic screening methods by new high-throughput genome-
wide screening and massively parallel sequencing approaches [3]. As a result, genomics 
research has the potential to aid clinicians in their task of estimating disease risk, as well as 
individualizing treatment modalities. This constitutes the basis of Genomic Medicine, a new 
specialty that promises to enhance opportunities for the customization of patient care 
including the personalization of conventional therapeutic interventions [4].  
Although the concept of Genomic or Personalized Medicine is relatively new, its 
intellectual predecessors have been around for some considerable time. Thus, aAround 400 
B.C.E., Hippocrates of Kos (460 B.C.–370 B.C.E.) stated that “… it is more important to 
know what kind of person suffers from a disease than to know the disease a person suffers”. 
AlsoIn addition, Ibn Sina (c.980-1037 C.E.) stated opined that “...in the make-up of most 
people there is somewhere a natural tendency to get out of order, some congenital weakness 
in one particular organ, tissue or system”. Ibn Sina called termed this a “personal disposition” 
and put forward the view that each patient is toshould be looked upon as a distinct and 
separate case. The first application of “Genomic Medicine” is codified in the Talmud. The 
Talmud (Yevamot 64b) relates Rabbi Judah the Prince’s ruling [2nd century B.C.E.] that if a 
woman’s first two children had died from blood loss after circumcision, the third son should 
not be excused circumcisioned. Rabbi Simeon ben Gamliel disagreed and ruled that the third 
son mightay be circumcised, but if this infant also died then the fourth child should not be 
circumcised. These two Rabbis did however agreed that the abnormal bleeding tendency was 
hereditary, but disagreed as to how many repeatitive events were required to establish a 
pattern and thereforejustifying exemption of a child from circumcision.These ancient 
statements and examples together probably encapsulate the essence of modern personalized 
genomic medicine. At present, several international organizations and research consortia are 
harmonizing their efforts with a view toto the aim of supporting the translation of genomic 
research into clinical practice so that genomic medicine can ultimately be used to benefit the 
global community (Table 1). 
The Genomic Medicine Alliance [GMA; 101] is a newly established global academic 
research network. It aims to build and strengthen collaborative ties between academics, 
researchers, regulators and those members of the general public who are interested in genomic 
medicine. The GMA focuses particularly on the translation of new research findings into 
clinical practice in developed, but most importantly, in developing countries.  
 
Aims and goals of the Genomic Medicine Alliance 
 
First and foremost, the GMA aims to: (a) Encourage and catalyze multidisciplinary 
collaborative research between partner institutions and scientists, particularly from developing 
countries, (b) Liaise between research organizations, clinical entities and regulatory agencies 
in areas related to genomic medicine, (c) Facilitate the introduction of pharmacogenomics and 
advanced omics technologies into mainstream clinical practice, (d) Propose guidelines and 
draw up recommendations in all areas pertaining to genomic medicine, in close collaboration 
with other scientific academic entities, agencies and regulatory bodies, and, (e) Develop 
independently and coordinate, in close collaboration with partner institutions, and coordinate 
educational activities in the area of genomic medicine. 
The main goal of the GMA is to encourage stronger collaboration between genomics 
research in developed and developing/low resourced countries. Such a stronger strengthening 
of collaboration is likely to create benefits for all parties. Developing countries will 
undoubtedly benefit from training opportunities, knowledge exchange, and from expanding 
transnational networks. Developed countries are likely to benefit through comparative work 
on families with rare diseases or unique clinical features and rare diseases. Considering that 
approximately 85% of the world’s population live in developing countries, this represents a 
major potentialopportunity, and to access a hitherto largely untapped, source of information 
on and biosamples from people with rare disorders. Rare disorders, while important to 
understand for the affected patient and their families, have also provided key insights which 
have led leading to breakthroughs in our understanding of gene function in disease and 
development. They have also played a crucial role in the identification of pathways that are 
essential to human health [110]. Further, a key requirement for the global success of GMA 
will be to prepare the path from genomics research to Genomic Medicine, by encouraging and 
undertaking multicenter research projects in key sub-disciplines. To this end, GMA activities 
aim to contribute in to the transition from genomics and pharmacogenomics research to 
Genomic Medicine, viz. Public Health Genomics, Ethics in Genomics (or ‘genethics’), 
Genome Informatics, the genetics education of healthcare professionals, genetics awareness 
of general public and health economic evaluation in relation to genomic medicine. Even if 
genomic and pharmacogenomics research are represent the bedrock of genomic medicine, 
supporting pillars will still need to be erected for the superstructure to hold: The areas 
identified in Figure 1 constitute these pillars. At present, although the foundations of genomic 
medicine are becoming stronger and met withbeing attributed ever- increasing hopes and 
expectations, the pillars upon themselves are still largely under construction.  
GMA research activities are accompanied by an International Scientific Advisory 
Committee comprising 14 internationally renowned scientists in the field, from Asia (Ming Ta 
Michael Lee) and the Middle East (Fahd Al-Mulla) to Europe (Angela Brand, David N. 
Cooper, Vita Dolzan, Milan Macek Jr, George P. Patrinos, Barbara Prainsack, Alessio 
Squassina, Effy Vayena, Athanassios Vozikis) and the USA (Paolo Fortina, Federico 
Innocenti, Marc S. Williams). Administrative assistance is provided by the Golden Helix 
Foundation [102] staff. Registration with the GMA is free-of-charge, to encourage the 
participation of researchers from developing and low-income countries. Upon registration, 
members specify their research interests so that they can be directed to research projects and 
training opportunities that suit their needs.  
 GMA research activities span six different Working Groups, namely Genome 
Informatics, Pharmacogenomics, Cancer Genomics, Public Health Genomics, Genethics and 
Economic Evaluation in Genomic Medicine. Each of the Working Groups’ activities are 
coordinated by the corresponding Working Group and Activity leaders in conjunction with 
Senior National Representatives from each of the >50 countries from which the >250 current 
GMA members (April 2014) originate (Fig. 2). Below, we summarize some of the key GMA 
research projects. 
 
Current research projects among GMA members 
 
Genome Informatics Working Group 
Documentation of the incidence of genetic disorders in different populations, 
particularly in those developing countries with a high incidence of genetic diseases and/or 
consanguinity can be particularly helpful in the context of adopting national prevention and 
screening programs [5]. GMA members currently participate in the development of three new 
National/Ethnic Genetic databases for the Kuwaiti, Moroccan and Bahraini populations to 
document the incidence of genetic disorders in these countries. In addition, five preexisting 
National/Ethnic Genetic databases for the Lebanese, Serbian, Cypriot, Greek and Egyptian 
populations are currently being migrated to the new ETHNOS software [6], which has 
recently been upgraded to include new data querying and visualization functionalities [7]. The 
long-term goal is to expand this concept such that the ETHNOS software supports the 
development of several National Genetic databases [111], based on the data warehouse 
principle and pre-existing guidelines [8] that will be assigned to senior human geneticists in 
the corresponding populations in order to coordinate their curation and further data [5]. 
Members of the GMA have also helped to develop an electronic tool to translate 
pharmacogenomics research results into a format that is meaningful for clinicians [9]. Such a 
project is proceeding in close collaboration with other major European research initiatives, 
such as RD-Connect [112] in order to harmonize and develop common standards for 
databases and patient registries for rare diseases, and most importantly to develop clinical 
bioinformatics solutions, including data mining and knowledge discovery tools for the 
analysis and integration of molecular and clinical data to promote the discovery of new 
disease genes, pathways and therapeutic druggable targets. 
 
Pharmacogenomics Working Group  
Pharmacogenomics holds out the promise of rationalizing drug treatment by by 
optimizing the balance between treatment efficacy and toxicity based upon a comprehensive 
understanding of the impact of genomic variants combined with other patient-based and 
environmental factors. The Pharmacogenomics Working Group, in close collaboration with 
the Golden Helix Foundation, is currently taking part in the Euro-PGx project [113], in which 
26 European populations are participating. More specifically, the Euro-PGx project aims to 
(a) determine the incidence [GEORGE: population frequencies?] of pharmacogenomics 
biomarkers to optimise medication modalities and to minimize adverse reactions by 
genotyping, in conjunction with the Pharmacogenomics for Every Nation Initiative [PGENI; 
114], 1,936 pharmacogenomically-relevant genetic variants in 231 absorption, distribution, 
metabolism, and excretion–toxicity (ADMET)-related pharmacogenes, which would assist in 
prioritizing medication selection in participating developing countries and, (b) develop off-
the-shelf solutions for pharmacogenomic testing in participating developing countries. 
Preliminary findings suggest that European populations display functionally significant 
differences in terms of >130 pharmacogenomic biomarkers; the replication of these findings 
in larger population samples would establish a common framework for pharmacogenomic 
testing in developing countries. 
The Pharmacogenomics Working Group has sought to provide proof- of- principle of 
the use of whole-genome sequencing for pharmacogenomic testing, by resequencing with 
high coverage almost 500 whole genomes, mostly from Caucasian populations. This project 
not only revealed a vast number of novel potentially functional variants in a total of 231 
pharmacogenes, as indicated by in silico analysis, but also demonstrated the value of whole-
genome sequencing for pharmacogenomic testing by capturing over 18,000 variants in these 
pharmacogenes; this compares with just 250 variants that would have been identified in these 
genes using the most comprehensive pharmacogenomics screening assay currently available 
[10]. 
 
Public Health Genomics Working Group  
Public Health Genomics represents the responsible and effective translation of 
genome-based knowledge and technologies into public policy and health services for the 
benefit of population health [11]. To this end, the Public Health Genomics Working Group is 
undertaking nationwide studies to better understand the level of the general public’s genetics 
awareness including their attitudes to genomic testing and the level of healthcare 
professionals’ (i.e. physicians, pharmacists, nutritionists, etc) genetics education. So far, such 
surveys have yielded some very interesting findings [12, 13] highlighting the relative lack of 
healthcare professionals’ genetics education and general public’s genetics awareness as 
perhaps one of the biggest obstacles to the widespread implementation of Genomic Medicine 
[14,15]. They have also shown the plural general utilityies of genomic testing for individuals 
including the public’s remarkable level of interest in participating in genomic research 
participation [16,17]. Such surveys are currently being replicated in other European countries 
to confirm these findings. To this end, GMA members co-organize educational events 
revolving around pharmacogenomics and Genomic Medicine in various European countries; 
these are endorsed by the GMA and partly funded by the Golden Helix Foundation and other 
entities [18]. 
The Public Health Genomics Working Group has engaged with a stakeholder analysis 
to determine the measures to be undertaken to expedite the genomic information-based 
medical decision- making process. 
 
Genethics Working Group  
Several ethical issues confront those of us who are committed to the practice of 
Genomic Medicine, including the regulation of genetic testing, the governance of genetic 
research, and genomic data sharing in an ethical and publicly accountable way [19]. The 
GMA Genethics Working group also explores the landscape of direct-to-consumer (DTC), 
beyond-the-clinic (BTC) [20] and over-the-counter (OTC) genetic tests in various European 
countries, including Greece [12], Slovenia, Italy and Serbia. It is particularly important to 
harmonize policies that safeguard the general public and ensure that they are become better 
informed with respect to the various attendant risks from this type of testing. Currently, 
regulation ofn these issues is lacking in many European countries, as well as at a central level 
in the form of a directive of the European Medicines Agency for both OTC and DTC genetic 
testing [21]. The GMA has recently produced an opinion article to highlight the various types 
of OTC genetic tests currently available [22]. GMA members are also working together with 
the National Genetic Societies and National Ethics Committees to establish guidelines to 
cover ethical, legal and social issues pertaining to genetic testing.  
 
Economic Evaluation in Genomic Medicine Working Group  
A key factor in expediting the adoption of Genomic Medicine in clinical practice 
would be the demonstration of its cost-effectiveness (as the “fourth hurdle” in health care, 
after safety, efficacy and quality). The real cost effectiveness of involving genomics in 
medicine is unknown excepting certainapart from some rather limited studies in 
pharmacogenomics and hereditary cancer syndromes. Realizing its effectiveness would be a 
crucial step towards convincing policy makers of the utility of genomics in healthcare as a 
means to reduce the cost of treatments, as well as the overall burden and consequences of 
diseases at the national level [23,24]. Currently, GMA members are involved in cost-
effectiveness and cost-utility analyses of warfarin (Croatia), acenocoumarol (Serbia and 
Greece) and clopidogrel (Serbia) anticoagulation treatments, and preliminary findings suggest 
that warfarin treatment is indeed cost-effective in Croatia [Mitropoulou C, Fragoulakis V, and 
co-workers, in preparation]. Future work is already in progress and includes drugs for cancer 
and hematologic malignancies treatment, while it is envisagedioned that the workgroup will 
eventually develop and evaluate standardized methodologies for economic evaluation of 
genomic medicine [25], which will be of utmost importance in such a rapidly evolving 
discipline.  
The GMA has recently endorsed the production of the textbook “Economic Evaluation 
in Genomic Medicine” that is co-authored by two GMA Scientific Advisory Committee 
members and will be published by Elsevier/Academic Press in early 2015.   
 
Future perspectives: A roadmap of GMA activities 
 
The GMA is a new initiative in the field of Genomic Medicine with the primary goal 
of encouraging the participation of developing and low-resourced countriessettings. In 
contrast to other Genomic Medicine initiatives and consortia (Table 1), the GMA has several 
unique features as a research consortium, namely free membership, a flat governance 
structure and above all, a commitment to bring together genomics research institutions from 
developing countries with those from developed countries. The official inaugural meeting of 
the GMA will be the forthcoming 2014 Golden Helix Symposium in Belgrade, Serbia (30 
October - 2 November 2014). 
The rapid expansion of the GMA membership baseis is a top priority of the 
International Scientific Advisory Committee. The focus will be placed primarily on 
developing countries in the Middle East, Asia and Latin America. Another route to expanding 
the membership base will be official partnerships with other Genomic Medicine consortia and 
international collaborative efforts. To this end, there is already a memorandum of 
understanding in place between the GMA and the SEAPharm consortium to pursue common 
goals particularly in the field of Pharmacogenomics, while GMA Scientific Advisory 
Committee members participated in the National Human Genome Research Institute-
supported Global Leaders in Genomic Medicine meeting in Washington DC, USA [January 8-
9, 2014; 116] 
 An important milestone for GMA was the recent agreement with Karger to establish 
the international peer-reviewed journal Public Health Genomics [115] as the Official GMA 
journal. Public Health Genomics is the leading bimonthly international journal focusing on 
the translation of genome-based knowledge and technologies into public health, health 
policies and healthcare as a whole. This partnership not only provides GMA members with a 
highly respected publication forum for to publish their original research findings but also with 
discounts on journals and books. 
 Regarding the various ongoing GMA research activities, the focus will be firmly 
placed on those projects that will deliver tangible results in relation to the translation of 
genomics research into clinical practice, e.g., the elucidation of the molecular basis of rare 
disorders, bioinformatics solutions to translating genomic results into clinically meaningful 
formats and accommodating whole genome sequencing data storage in an aggregate manner. 
Another, strong focal point for the next two years will be projects in the field of health 
economic evaluation in genomic medicine to study the cost-effectiveness of 
pharmacogenomic testing. In addition, and in order to support the transnational mobility of 
students and junior researchers, the GMA plans to launch short- and long-term research 
fellowships for early-stage researchers from developing countries to pursue research in 
Centers of Excellence in developed countries. The GMA envisages doing this in collaboration 
with the Golden Helix Foundation and other charities. 
 Last but not least, the GMA will continue to endorse conferences and educational 
activities in the field of Genomic Medicine in Europe, the Middle East, Latin America and 
Southeast Asia. In addition, in conjunction with the Golden Helix Foundation [102], it has 
already established the Golden Helix Summer Schools [116]. Thisese international initiative 
in the field of Genomic Medicine and Genome informatics aims to provide researchers around 
the world with the opportunity to expand their knowledge in the rapidly evolving field of 
Genomic Medicine and to exchange innovative ideas in the most conductive environment of 
the Greek islands.  
 In essence, the GMA, aspires to become a focal point for harmonizing research 
activities in the field of genomic medicine between developed and developing countries and 
while further cultivate helping to pave the way for a smoother transition from genomics 
research in to genomic medicine. 
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Figure 1. 
Graphical depiction of the GMA research activities that aim to translate Genomics 
Research and Pharmacogenomics into Genomic Medicine (see also text for details). 
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Figure 2. 
Outline of GMA membership status. The GMA is coordinated by a 14-member Scientific 
Advisory Committee, assisted by the Working Group leaders and Senior National 
Representatives from more than 50 countries, from which the GMA members originate. 
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Regular Members 
Table 1. Summary of the major international organizations involved in the field of Personalized Medicine. N/A: Not yet available 
Organization Type Activities description Region Website 
European Alliance for Personalized 
Medicine (EAPM) 
Policy - advocacy group 
EUAPM aims to position personalized medicine within 
the broader context of personalized healthcare, 
promote the understanding of personalized healthcare 
by patients, professionals and policy makers, catalyze 
the shaping not only of EU policy discussions, 
introduce incentives for personalized healthcare and 
create a favorable reimbursement environment for 
personalized medicines & companion diagnostics. 
Europe 103 
PerMed European project 
PerMed aims to complement existing activities by 
identifying and promoting promising research 
topics, developing strategic research and 
innovation agendas in Europe and beyond, and to 
bringing forward the implementation of 
Personalized Medicine for the benefit of society at 
large. 
Europe 104 
European Personalized Medicine 
Association (EPEMED) 
Non-profit Organization 
EPEMED aims to make personalized medicine a 
practical reality in Europe by focusing on the patient’s 
access to innovations in this area, particularly for with 
respect to co-dependent drug-companion diagnostics 
technologies.  
Europe 105 
European Society for Predictive 
Medicine (EUSPM) 
Scientific Society 
EUSPM aims to promote predictive medicine among 
healthcare professionals and to engage in educational 
activities to promote the concept of predictive 
Europe 106 
medicine.  
Personalized Medicine Coalition 
(PMC) 
Policy - advocacy group 
PMC represents a broad spectrum of more than 225 
innovator, academic, industry, patient, provider and 
customer communities. It aims to educate both the 
general public and policymakers by promoting new 
ways of thinking about health care and by advancing 
the understanding and adoption of personalized 
medicine and its products for the benefit of patients.   
United States 107 
South East Asian Pharmacogenomics 
Research Network (SEAPHARM) 
Research Consortium 
SEAPHARM aims to strengthen mutual cooperation 
and facilitate sustainable and equitable growth of the 
Pharmacogenomics community, and to promote further 
cooperation and linkage through seminars, exhibitions, 
workshops, technical assistance, scholarship schemes, 
training, and joint R&D projects, and where possible to 
exchange information, experience, know-how, 
technology and best practices, in the field of 
Pharmacogenomics. 
Southeast Asia 108 
Global Alliance for Global Health 
(GA4GH) 
Research Consortium 
GA4GH aims to accelerate progress in human health 
by helping to establish a common framework of 
harmonized approaches to enable effective and 
responsible sharing of genomic and clinical data, and 
by catalyzing data-sharing projects that drive data 
sharing and demonstrate its value. 
International 109 
Global Genomic Medicine 
Consortium  (G2MC) 
Research Consortium G2MC aims to develop into a global effort to serve the 
goals of personalized medicine 
International N/A 
 
